Archive for the ‘Gene Therapy Research’ Category

COSTA MESA, Calif., April 1, 2013 /PRNewswire/ --Emulex Corporation (ELX) today announced that Gene Frantz and Greg Clark have been appointed to the Emulex Board of Directors. Mr. Frantz and Mr. Clark add expertise across the spectrum of technology and telecom sectors.

(Logo: http://photos.prnewswire.com/prnh/20120403/NE81278LOGO)

"I have known Gene Frantz for several years and admired his demonstrated abilities and knowledge of the IT marketplace. I have also more recently come to know Greg Clark and I have been very impressed with his executive experience and insights concerning the network performance management market which Emulex is just entering. I believe that the Board has made excellent choices," said Jim McCluney, chief executive officer (CEO), Emulex, "and on behalf of the Board, we welcome both to the team."

Mr. Frantz is a business executive with deep technology and telecom experience. He was most recently a partner of TPG Capital ("TPG") having worked there from 1999 to 2012. Prior to joining TPG, Mr. Frantz worked at Oracle Corporation and Morgan Stanley. Mr. Frantz previously served on the boards of directors of ALLTEL, Avaya, Freescale Semiconductor, Network General, MEMC Electronic Materials, Paradyne Networks (acquired by Zhone Technologies), SMART Modular Technologies, Inc., and Certance Holdings (formerly a division of Seagate Technology acquired by Quantum Corp.). Mr. Frantz received an M.B.A. from Stanford Graduate School of Business and a B.S. in Business Administration from the University of California, Berkeley.

Mr. Clark has more than 23 years of leadership experience successfully growing technology companies through innovation, focus and execution. He has a strong operations and technology background that spans security, cloud services, supply chain and network management. Mr. Clark has been CEO and member of the Board of Directors of Blue Coat Systems, Inc. (BCSI) since August 2011. During his tenure Mr. Clark led the company through take-private transaction and associated restructuring. Under Mr. Clark's leadership BCSI has returned to double digit revenue growth with industry leading margins. Prior to joining Blue Coat, Mr. Clark was President and CEO of Mincom, a global software and services provider to asset-intensive industries. At Mincom, he expanded the company's market opportunity and revenue via the addition of cloud-based solutions and a modernization of Mincom's legacy products. The company was acquired by the ABB Group in July 2011. Before joining Mincom, Mr. Clark served as President and Chief Executive Officer at E2open, a leader in supply chain networks. Mr. Clark was one of E2open's founders and transformed E2Open from an early startup into a market-leading solutions provider supporting more than 15,000 customers worldwide. Earlier in his career, Mr. Clark founded security software firm Dascom. In 1999, IBM acquired the company, and the technology became the foundation for Tivoli's security product line. At IBM, Mr. Clark was a Distinguished Engineer and Vice President of IBM's Tivoli Systems, where he was instrumental in defining and selling IBM security and management products. He previously held senior roles with global IT companies, such as AT&T Unix Software Operation and Unix System Labs. Mr Clark serves as an independent director at the Global Healthcare Exchange (GHX).

"I am honored to be asked to join the Emulex Board," said Gene Frantz. "I look forward to working with the rest of the Board to help Emulex to realize its potential for stockholders as a leader in the connectivity and network communications markets."

"Joining the Emulex Board is an exciting opportunity for me," said Greg Clark. "The management and Board of Emulex have set an ambitious path, and I am happy to contribute my expertise for the benefit of the company and its shareholders."

"We are very pleased to have worked collaboratively with Emulex to add Gene Frantz and Greg Clark to its Board," said Jesse Cohn, a Portfolio Manager at Elliott Management, which manages funds that together are the largest shareholder of Emulex. Mr. Cohn continued, "Jim and his team at Emulex have a solid strategy and have developed leading technology in their focused markets and we believe that the addition of Gene and Greg to the Board will help Emulex to realize meaningful value for stockholders."

Emulex collaborated with Elliott in the addition of Mr. Eugene J. Frantz and Mr. Gregory S. Clark to the Emulex Corporation Board of Directors. The agreement, which includes limitations on acquisitions of additional Emulex shares by Elliott, is being filed with the SEC by Emulex.

To learn more about Emulex, please visit: http://www.emulex.com

Go here to see the original:
Emulex Appoints Gene Frantz and Greg Clark to its Board of Directors

RT catches the eye of The Colbert Report
On Tuesday, we reported how lawmakers at the Tennessee State Capitol were concerned about a particular sink that was thought to be a Muslim foot bath. The al...

By: RTAmerica

See the rest here:
RT catches the eye of The Colbert Report - Video

United States of Monsanto: GMO giant is now litigation proof
After President Obama signed the Agriculture Appropriations Bill into law on Tuesday, hundreds of thousands of people have voiced their opposition to H.R. 93...

By: RTAmerica

Read more:
United States of Monsanto: GMO giant is now litigation proof - Video

When is a fish not a fish but a drug? When government regulators take old laws and twist themselves into knots trying to apply them to new technology.

In the emotionally charged battle over the safety and appropriateness of genetically modified foods, people on both sides agree that the way the government oversees genetically modified plants and animals is patchy, inconsistent and at times just plain bizarre.

Soon, analysts say, the system may be stretched to the breaking point. That could leave many genetically modified crops unregulated a worry for those who fear environmental and safety risks or who believe that government vetting is key for broad public acceptance.

Its a bit of a mess, said science policy expert Jennifer Kuzma of the University of Minnesota.

The web of regulations used to govern genetically engineered species draws on more than 10 laws, all written for other purposes. Some were crafted to address issues such as tainted drugs, wheat spiked with sawdust and pollution by industrial chemicals.

The results can be odd.

Atlantic salmon that grow quickly thanks to a growth hormone gene from

another salmon species are deemed new animal drugs because the U.S. Food and Drug Administration decided to regulate genetically engineered animals under the Food, Drug and Cosmetic Act of 1938.

A cotton plant that makes insect-killing proteins with the help of a gene from a soil bacterium is a pesticide in the eyes of the U.S. Environmental Protection Agency, which regulates the crop under the Federal Insecticide, Fungicide and Rodenticide Act of 1972.

In what some critics deem the biggest contortion, many genetically modified crops are classified as potential plant pests so that the U.S. Department of Agriculture may preside over them through the Federal Plant Pest Act of 1957 even though the key traits added to the plants have nothing to do with pests.

See original here:
Food's genetic modification introduces brave new world of regulation

Public release date: 2-Apr-2013 [ | E-mail | Share ]

Contact: Greyling Peoples g.peoples@elsevier.com 31-204-853-323 Elsevier

Cambridge, UK, April 2, 2013 Preimplantation genetic diagnosis (PGD) technologies allow identification of genetic disorders in human preimplantation embryos after in vitro fertilization (IVF) and before the embryo is transferred back to the patient. This technique allows couples with a high-risk of passing on inherited diseases, to increase their chances of having a healthy baby. Despite the theoretical benefits of PGD, clinical outcomes using these technologies vary, possibly because of the need to remove one or more cells from the embryo using biopsy.

In a recent study published in Reproductive Biomedicine Online, a group of researchers from Italy and the United Kingdom sought to achieve diagnose of genetic disease in embryonic DNA without the use of a biopsy. By extracting fluid from human embryos at the blastocyst stage they found that it contains DNA from the embryo. Blastocysts are 5 or 6 day old embryos and are at the last free-living stage that can be studied in the laboratory prior to transfer into the uterus. They contain between 50 and 300 cells that surround a fluid-filled cavity called the blastocoels. The researchers carefully removed fluid from the blastocoel, leaving the cells intact; the sampled blastocysts were subsequently cryopreserved. Analysis of this fluid showed that it contained cell-free DNA in a state good enough to determine several known genes of the sex chromosomes by polymerase chain reaction (PCR); whole genome amplification and followed by analysis using a specialized tool for genetic testing called a DNA microarray were also used and revealed whether the embryos had a normal number of chromosomes chromosome abnormalities are one of the main causes of miscarriage and failure of embryos to form pregnancies during IVF treatments.

"This is the first time that embryonic DNA has been detected in the human blastocyst without the use of biopsy," explained lead researchers Dr. Simone Palini Ph.D., from the IVF Unit at Cervesi Hospital in Cattolica, Italy and Dr. Galluzzi from University of Urbino in Italy and Dr. Dagan Wells from University of Oxford, United Kingdom.

"This is a technique that most embryologists can easily master," Dr. Buletti who directs the IVF team at Cervesi Hospital Cattolica and Prof. Magnani, Chairman of the Department of Biomolecular Sciences of the University of Urbino, added. "More work needs to be done to confirm our results, but we hope that this approach will ultimately help infertile couples achieve their dream of having a family. It may also improve the options for families affected by severe inherited conditions, helping them to have healthy babies."

"Even though it is only a preliminary finding, this approach may allow for genetic testing of the embryo without the complexity of cell sampling," Dr. Joe Leigh Simpson MD, Senior Vice President for Research Programs, March of Dimes Foundation and President, International Federation of Fertility Societies (IFFS), a pioneer in reproductive medicine and genetics, commented on the research.

###

This article is "Genomic DNA in human blastocoele fluid" by S. Palini, L. Galluzzi, S. De Stefani, M. Bianchi, D. Wells, M. Magnani, C. Bulletti (10.1016/j.rbmo.2013.02.012).The article is currently an Article in Press in Reproductive Biomedicine Online, (March, 2013), published by Elsevier.

Notes for Editors

Go here to see the original:
Sampling of embryonic DNA after IVF without biopsy

SHERWOOD, Ore., April 2, 2013 /PRNewswire/ --Entia Biosciences (ERGO), a food science biotechnology company and emerging leader in the field of Nutrigenomics, has now received three Patent Notices of Allowance covering the use of Ergothioneine and its genetic transporter in the treatment of a wide variety of diseases, including those affecting the immune and central nervous systems. Notices from the United States Patent and Trademark Office and the Israel Patent Office were received in March and from the Canadian Intellectual Property Office in December.

Ergothioneine is a powerful amino acid and master antioxidant that is acquired exclusively from the diet and carried by a unique and specific transporter (human gene symbol SLC22A4) to cells throughout the body that are fighting damage and death from oxidative stress and toxic free radical reactions. Research conducted by Entia since 2011 has confirmed significant transporter activity in diabetes, arthritis, and several other serious non-communicable chronic conditions, suggesting an important physiologic role for Ergothioneine and its transporter in diseases affecting millions of people world-wide.

Discovered in 2005 by Dr. Dirk Grundemann at the University of Cologne (Germany), SLC22A4 is a sodium-ion dependent transporter that efficiently and specifically carries Ergothioneine across the cell membrane to erythrocytes (red blood cells), progenitor stem cells, and monocytes (white blood cells) (Grundemann, 2005). Variations in SLC22A4 have been associated with susceptibility to inflammatory disorders, such as rheumatoid arthritis and Crohn's disease, and expression has been documented in a variety of human tissues. Entia licensed the exclusive world-wide diagnostic and therapeutic rights to the discovery from the University of Cologne in 2010 and Dr. Grundemann currently serves on Entia's Scientific Advisory Board.

Found in naturally high concentrations almost exclusively in mushrooms and other fungi, Ergothioneine is transferred directly from these sources into the soil, where it is taken up by plants and grazing mammals. For thousands of years, our hunter/gatherer genetics have relied on this process to maintain adequate levels of Ergothioneine to prevent or delay the onset and progression of disease. Entia theorizes introduction of modern agricultural practices in the past century, such as the heavy use of chemical fertilizers, herbicides, pesticides, and over tilling of the soil, has been gradually eradicating mushrooms from our farmland and depleting Ergothioneine from the food supply. During this same period, our dietary habits have been changing, which Entia believes is further accelerating deficiency in the general population and may be a contributing factor in the dramatic increases we are now seeing in diabetes, arthritis, neurodegenerative, and other debilitating diseases. This deficiency theory is supported by human blood testing conducted in the late 1920s (Salt, 1931) that showed "normal" Ergothioneine levels nearly double those found by Pennsylvania State University in 2010 (Weigand-Heller, 2012).

Dr. Solomon Snyder of Johns Hopkins University School of Medicine has suggested that Ergothioneine is as potent as glutathione and because of its dietary origin and the toxicity associated with its depletion, it may represent a new vitamin whose physiologic roles include antioxidant cytoprotection. Dr. Snyder further believes that the high density of Ergothioneine within mitochondria implies a unique role in protecting mitochondrial DNA from damage induced by free radicals and reactive oxygen species (Snyder, 2009). Mitochondria are cytoplasmic organelles responsible for life and death. Evidence from animal and clinical studies suggest that mitochondria play a critical role in aging, cancer, diabetes and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (Simon, 2004; Lin, 2006; Reddy, P.H., 2009).

About Entia Biosciences, Inc.

Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.

For more information, please visit our web sites at http://www.entiabio.com or contact:

Devin Andres Chief Operating Officer Entia Biosciences, Inc. 13565 SW Tualatin-Sherwood Rd Sherwood, OR, 97140 Phone: 503-334-3575 Email: info@entiabio.com

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2012 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Excerpt from:
Entia Receives Notices of Allowance for its Ergothioneine and Genetic Transporter Patents from the United States ...

Until now, experts believed this type of epilepsy came from a neurological trauma, such as a hit to the head. Picture: ThinkStock Source: Supplied

AUSTRALIAN researchers have discovered a gene they believe is responsible for the most common form of epilepsy, opening the door to genetic screening.

The researchers also suspect a link between this gene and other neurological issues, such as autism and some psychiatric disorders.

The discovery, by researchers at the Universities of Melbourne and South Australia, has been described as a major breakthrough.

Until now, many experts believed this type of epilepsy came from a neurological trauma, such as a hit on the head.

"This is going to completely shift thinking," Professor Ingrid Scheffer, the study's senior author and a paediatric neurologist, said. "Instead of saying 'we don't know the cause', they can test for this gene."

About 25 genes for rarer types of epilepsy have already been found - more than half of them by Australian scientific groups.

But this gene causes focal epilepsy, which affects 60 per cent of people with epilepsy.

In this form of the disorder, the seizure comes from a specific part of the brain, such as the frontal cerebral cortex, although the gene causes seizures coming from different parts of the brain in different people. Seizures most commonly come from the temporal lobe or the frontal lobe.

"For the patient the discovery means a few things," Professor Scheffer said.

See the rest here:
Gene test hope for common epilepsy

By Barbara Bronson Gray HealthDay Reporter

WEDNESDAY, March 27 (HealthDay News) -- Critical clues to understanding who is at the greatest risk for particular types of cancer may be found in "spelling mistakes" contained in a person's DNA.

In a step toward personalized medicine and the ability to better understand individual risk factors for three common hormone-related cancers, a large team of international researchers have unveiled what might be the clearest picture to date of the genetic alterations associated with some forms of the disease.

Although more research is needed, the study authors predict that genetic testing to help determine a person's risk for some of the most potentially deadly cancers may be available within five to 10 years.

"We think the most immediately practical application will be in people already at risk for the disease and going through the genetic counseling process," said Douglas Easton, a professor of genetic epidemiology at the University of Cambridge, in England.

A combination of five studies that include work from 160 different research groups has identified more than 80 genetic errors that are linked to increased risk of breast, prostate and ovarian cancers. The research was published March 27 in the journal Nature Genetics.

More than 2.5 million people worldwide are diagnosed with these three types of cancers each year, according to the researchers.

Everyone has some of the so-called spelling mistakes, often called "snips" (single nucleotide polymorphisms, or SNPs), the researchers said. Problems are signaled by errors in the sequence of genetic elements (bases), where letters representing the elements -- A, G, C and T -- are incorrectly placed.

The sequence of bases in a portion of a DNA molecule, called a gene, carries the instructions that are needed to create a protein. Although some errors affect small things, others may be responsible for increasing vulnerability to certain forms of cancer. The impact on a person depends on where on the strand of DNA the genetic alteration is located.

The studies from the European-based consortium -- collectively known as the Collaborative Oncological Gene-Environment Study, or COGS -- compared 100,000 patients with breast, ovarian or prostate cancer to 100,000 healthy people.

Read more:
More genetic insights into three types of cancer

March 31, 2013

Brett Smith for redOrbit.com Your Universe Online

Researchers at Stanford University have developed a basic computer using genetic material, according to a report in the journal Science.

The team said that the tiny biological transistors they have developed could potentially revolutionize medicine in the future.

Were going to be able to put computers into any living cell you want, lead author Drew Endy explained to the San Jose Mercury News. Were not going to replace the silicon computers. Were not going to replace your phone or your laptop. But were going to get computing working in places where silicon would never work.

Endy, who came to Stanford from the Massachusetts Institute of Technology, co-founded the BioBricks Foundation, which supports free-to-use standards and technologies for engineering biology.

Any place you want a little bit of logic, a little bit of computation, a little bit of memory were going to be able to do that, said Endy.

For example, gene-based biological computers could determine if a certain toxin is present inside a cell or react to treatment within an individual cell.

Traditional transistors that are found in conventional computers control the flow of electrons in the form of the zeros and ones of binary code, the most basic machine language. Arranging multiple transistors together forms something called a logic gate, which serves as the basic building block of all computations performed by computers around the world.

The Stanford genetic transistors, which theyve dubbed transcriptors, use enzymes to manage the flow of RNA proteins along a strand of DNA, similar to the way a computer would use silicon transistors. Using about 150 letters of genetic code, the transcriptors could make a yes-or-no decision, such as determining if mercury is present within the cell.

See original here:
Biological Transistors Could Revolutionize The Future Of Medicine

RAGE CAGE (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Want some gear? US Store: http://seananners.spreadshirt.com EU Store: http://seananners.spreadshirt....

By: SeaNanners

Here is the original post:
RAGE CAGE (The Hidden) - Video

Why I Believe Bodyweight Training is BEST
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

See the original post:
Why I Believe Bodyweight Training is BEST - Video

By Rick Nauert PhD Senior News Editor Reviewed by John M. Grohol, Psy.D. on March 29, 2013

Unfortunately, antidepressant drug therapy does not work for everyone. But new research finds that improved identification of genomic predicators that is, how a persons genetic makeup might impact their response to medication will help future treatment of depression.

The National Institute of Mental Healths STAR*D study, the largest and longest study ever conducted to evaluate depression treatment, has determined that only one-third of individuals respond to the first medication prescribed for depression, and that another one-third do not have an adequate response despite being treated with several medications.

Thus, identifying predictors of antidepressant response could help to guide the treatment of this disorder.

A new study, published in Biological Psychiatry, discusses new initiatives for identifying genomic predictors of antidepressant response.

Many previous studies have searched for genetic markers that may predict antidepressant response, but have done so despite not knowing the contribution of genetic factors, saidKatherine Tansey, Ph.D., a psychiatric researcher at Kings College, London.

Our study quantified, for the first time, how much is response to antidepressant medication influenced by an individuals genetic makeup, said Tansey.

For the study, researchers estimated the magnitude of the influence of common genetic variants on antidepressant response using a sample of 2,799 antidepressant-treated subjects with major depressive disorder and genome-wide genotyping data.

They found that genetic variants explain 42 percentof individual differences, and therefore, significantly influence antidepressant response.

While we know that there are no genetic markers with strong effect, this means that there are many genetic markers involved. While each specific genetic marker may have a small effect, they may add up to make a meaningful prediction, Tansey added.

Read the original post:
Genetics Impacts Depression Meds’ Effectiveness

Design Talks: Timothy Prestero
Design that Matters, National Design Award winner for Corporate and Institutional Achievement, is a nonprofit design company that partners with social entrep...

By: cooperhewitt

See the original post here:
Design Talks: Timothy Prestero - Video

Italian health officials are allowing a handful of patients to continue with a controversial stem cell therapy amid protests from scientists that the treatments are unproven and unsafe.

The Stamina Foundation has been administering the therapy at the public hospital Spedali Civili of Brescia to people with a range of degenerative diseases. Their approach is based on mesenchymal stem cells, derived from bone marrow, which can become mature bone and connective tissue.

In 2011 the hospital agreed to host the research and assist with cell extraction and patient treatments, stirring protests from the medical community. "The hospital is not even listed among the 13 Italian authorised stem cell factories," says Michele de Luca, director and gene therapy programme coordinator at the Centre for Regenerative Medicine in Modena. After an inspection in 2012, Italian drug regulator AIFA ordered an immediate halt to Stamina's stem cell treatments at the hospital.

The AIFA report says the Stamina Foundation's treatment did not follow Italy's official path required for clinical approval. So far no scientific publications describing its effectiveness are available.

But the halt sparked protests among patients' families who believed the treatment was working. Some appealed to the courts, and as a result a few patients were allowed to go ahead with the therapy. On 15 March, a group of 13 Italian stem cell researchers published an open letter to the country's Minister of Health, Renato Balduzzi, asking him to shut down all of the Stamina Foundation's treatments at the hospital.

Instead Balduzzi signed a bill last week authorising the foundation to continue treatments in patients who had already begun the regime unless they are experiencing serious side effects.

If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.

Only subscribers may leave comments on this article. Please log in.

Only personal subscribers may leave comments on this article

Subscribe now to comment.

Link:
Italy pushes on with controversial stem cell therapy

Mar. 28, 2013 Human cells have an intrinsic capacity to destroy HIV. However, the virus has evolved to contain a gene that blocks this ability. When this gene is removed from the virus, the innate human immune system destroys HIV by mutating it to the point where it can no longer survive.

This phenomenon has been shown in test tube laboratory experiments, but now researchers at the University of North Carolina School of Medicine have demonstrated that the same phenomenon occurs in a humanized mouse model, suggesting a promising new target for tackling the virus, which has killed nearly 30 million people worldwide since it first appeared three decades ago.

A family of human proteins called APOBEC3 effectively restrict the growth of HIV and other viruses, but this action is fully counteracted by the viral infectivity factor gene (vif) in HIV. In the study, researchers intravenously infected humanized mice with HIV. They found that the most commonly transmitted strains of HIV are completely neutralized by APOBEC3 proteins when vif is removed from the virus.

"Without the vif gene, HIV can be completely destroyed by the body's own immune system," said J. Victor Garcia, PhD, professor of medicine at the UNC School of Medicine and senior author on the study. "These results suggest a new target for developing drugs fully capable of killing the virus."

Garcia and his colleagues pioneered the humanized mouse model used for these studies. The aptly named "BLT" mouse is created by introducing human bone marrow, liver and thymus tissues into animals without an immune system of their own. The mice have a fully functioning human immune system and can be infected with HIV in the same manner as humans. In previous research, Garcia and his team have effectively prevented intravenous, rectal, vaginal and oral transmission of HIV in the mice with pre-exposure prophylaxis (PrEP).

For the current study, Garcia and his colleagues also infected BLT mice with another, highly harmful strain of the virus. The results show that this strain of HIV does continue to replicate, even without vif, but at a much slower rate and without harming the human immune system. Further, the researchers found that virus replication in this case was limited to one tissue -- the thymus -- in the entire body.

"These findings demonstrate a fundamental weakness in HIV," said John F. Krisko, PhD, lead author on the study. "If this weakness can be exploited, it might eventually lead to a cure for HIV/AIDS," Krisko said.

The study appears March 28 in the online journal PloS Pathogens.

In addition to Garcia and Krisko, other study authors are Francisco Martinez-Torres, PhD, and John L. Foster, PhD, all of the Center for AIDS Research at the University of North Carolina School of Medicine.

Share this story on Facebook, Twitter, and Google:

Read more from the original source:
Innate immune system can kill HIV when a viral gene is deactivated

In Thursday's Healthier Me,scientists say they've discovered new ways in which small changes in our DNA can increase the risk for breast, ovarian, and prostate cancer.

It is a trove of new genetic information about cancer that could soon help millions of patients: researchers have found nearly 50 new markers for breast cancer, 26 for prostate cancer, and nearly a dozen for ovarian cancer.

Groundbreaking studies of more than 200,000 people in some 200 labs around the worldalmost doubled the number of gene variations known to affect risk for some of the deadliest cancers.

Thisnew genetic information could soon lead to new blood tests to help determine how much a person is at risk and how serious the cancer might be.

Because the research involved so many subjects, some of the tests should be in your doctor's office in a year or two, with others coming further down the road.

The explosion of genetic information has been made possible through the development of robotic machines capable of identifying the slight differencesin the DNA which signal cancer risk. Finding these variations used to take months or years; now it takes just days.

Dr. Fergus Couch, Mayo Clinic: "We started this project four years ago, and already we're at an endpoint where we can make tremendous benefits for the patients. We really thought we'd be doing this for 10, maybe 15 years before we'd see an outcome."

The tests will also help to identify more families with a high risk for cancer, allowing people like Julie Olbering -one of five girls -and her loved ones to make better-informed decisions

Experts say it's a gigantic step toward the goal of personalized medicine: giving individuals and families exactly the information and the treatment they need.

Read more here:
Healthier Me: Genetic Markers Reveal Cancer Risks

Public release date: 29-Mar-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, Mar 28, 2013Explosive growth in the field of tissue engineering and regenerative medicine has led to innovative and promising applications and techniques, many of which are now being tested in human clinical trials. Hot topics, research advances, and transformative publications that are driving the field forward are highlighted in a comprehensive overview of the field presented in Tissue Engineering, Part B, Reviews, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers (http://www.liebertpub.com). The article is available on the Tissue Engineering website (http://www.liebertpub.com/ten).

Matthew Fisher, PhD and Robert Mauck, PhD, Perelman School of Medicine, University of Pennsylvania, and Philadelphia Veterans Administration Medical Center, Philadelphia, PA, identify four key areas in which the field is progressing. The first main theme, in the area of tissue engineering, focuses on advances in grafts and materials, including human or animal tissue from which the cells are removed and the remaining scaffold is used to regenerate new tissues, as well as scaffolds made of new types of biomaterials. Second, in the field of regenerative medicine, the authors highlight the role of novel scaffolds and various growth and control factors in promoting tissue formation and, for example, bone healing.

In the article "Tissue Engineering and Regenerative Medicine: Recent Innovations and the Transition to Translation," (http://online.liebertpub.com/doi/full/10.1089/ten.teb.2012.0723) the authors identify two additional areas that signal progress in the field: the increasing number of applications advancing into clinical trials; and the growing use of novel types of cells, such as induced pluripotent stem cells.

"Considering the rapid pace of growth and development in regenerative medicine, it is imperative that we fully consider recent advances," says Reviews Co-Editor-in-Chief John P. Fisher, PhD, Professor and Associate Chair, Fischell Department of Bioengineering, University of Maryland, College Park, MD. "Dr. Matthew Fisher and Dr. Robert Mauck have wonderfully reviewed the efforts in the tissue engineering field over the past few years, highlighting advances in biomaterials, cell-based constructs, and translational endeavors."

###

About the Journal

Tissue Engineering is an authoritative peer-reviewed journal published monthly in print and online in three parts: Part A--the flagship journal; Part BReviews; and Part CMethods. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the Official Journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on the Tissue Engineering website (http://www.liebertpub.com/ten).

About the Publisher

See more here:
What advances are driving clinical applications of tissue engineering and regenerative medicine ?

Mutazione... Card Trick Magic N°2
Luce nel video migliorata! Spero di continuare così! Adesso un video ogni 2 giorni! :D.

By: IDr93

Read the rest here:
Mutazione... Card Trick Magic N°2 - Video

HUNTED BY MARIO (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Want some gear? US Store: http://seananners.spreadshirt.com EU Store: http://seananners.spreadshirt....

By: SeaNanners

Go here to see the original:
HUNTED BY MARIO (The Hidden) - Video

Resistance to Growing Stronger
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

See the article here:
Resistance to Growing Stronger - Video

EPIC Natural Bodybuilding Motivation 2013: Polska Genetics - My Way to the Top
Please share this video on Facebook and spread the motivation!!! Thank you so much for the support!! SUBSCRIBE: http://www.youtube.com/subscription_center?ad...

By: Mischa Janiec

Read more here:
EPIC Natural Bodybuilding Motivation 2013: Polska Genetics - My Way to the Top - Video

"Piss People Off" chest shoulder workout (THANK YOU)
MUSIC LINK: http://www.youtube.com/watch?v=2639OrgM0Mk Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://...

By: strengthcamp

Continued here:
"Piss People Off" chest

Autism (Understanding Autism, Autistic Children and Autistic Adults)
Ask Teal Website - http://www.askteal.com For thousands of years the human species has been left brain oriented. This is a term to describe the state of bein...

By: TheSpiritualCatalyst

Visit link:
Autism (Understanding Autism, Autistic Children and Autistic Adults) - Video

Why Deep Squatting is Critically Important
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

Continue reading here:
Why Deep Squatting is Critically Important - Video

Chest Traps Day
Just switched a few things up nothing too crazy. If you dont like high volume and busting ya ass then this workout isnt for you. ---GET 5% off my recommended...

By: PhysiquesOfGreatness

More here:
Chest